Search over 3,000 reports

    Human Papillomavirus Associated Diseases - Pipeline Insights, 2017

    Human Papillomavirus Associated Diseases - Pipeline Insights, 2017
    Date: Nov, 2017
    Type: Pharmaceutical Industry Report
    Pages: 199
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIPI0152
    DelveInsight's, "Human Papillomavirus Associated Diseases (HPV-AD) - Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs and vaccines for this area. This report also provides information on the therapeutic development for the Human Papillomavirus (HPV) Associated Diseases. It further provides comparative analysis at various stages covering Phase III, Phase II, Phase I, IND, and Pre clinical; therapeutics assessment by monotherapy products, combination products, drug molecule type and vaccine type (live/non-live). It also features the dormant and discontinued products.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
    Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases.
    Introduction
    Overview
    Pipeline Therapeutics: HPV-AD Drugs
    Comparative Analysis
    Late Stage Drugs (Phase III)
    Mid Stage Drugs (Phase II)
    Early Stage Drugs (Phase I and IND)
    Pre-clinical Drugs
    Therapeutic Assessment: Active HPV-AD Drugs
    Dormant Drugs
    Discontinued Drugs
    Pipeline Therapeutics: HPV-AD Vaccines
    Late Stage Vaccines (Phase III)
    Mid Stage Vaccines (Phase II)
    Early Stage Vaccines (Phase I)
    Pre-clinical Vaccines
    Mid Stage Vaccines (Phase II)
    Early Stage Vaccines
    Pre-clinical Vaccines
    Dormant Vaccines
    Discontinued Products
    Appendix
    Methodology
    Consulting Services
    About DelveInsight
    Contact Us
    Disclaimer
    Table 1: Total Drugs for HPV-Associated Diseases
    Table 2: Late Stage Drugs (Phase III
    Table 3: Mid Stage Drugs (Phase II
    Table 4: Early Stage Drugs (Phase I and IND
    Table 5: Pre-clinical Drugs
    Table 6: Assessment by Monotherapy Drugs
    Table 7: Assessment by Route of Administration
    Table 8: Assessment by Stage and Route of Administration
    Table 9: Assessment by Molecule Type
    Table 10: Assessment by Stage and Molecule Type
    Table 11: Dormant Drugs
    Table 12: Discontinued Drugs
    Table 13: Total Vaccines for HPV-
    Table 14: Late Stage Vaccines (Phase III)
    Table 15: Mid Stage Vaccines (Phase II)
    Table 16: Early Stage Vaccines (Phase I)
    Table 17: Pre-clinical Vaccines
    Table 18: Mid Stage Vaccines (Phase II)
    Table 19: Early Stage Vaccines (Phase I)
    Table 20: Pre-clinical Vaccines
    Table 21: Assessment by Monotherapy Vaccines
    Table 22: Assessment by Route of
    Table 23: Assessment by Stage and Route of Administration
    Table 24: Assessment by Live or Non-live Vaccines
    Table 25: Assessment by Stage and Live or Non-live Vaccines
    Table 26: Dormant Vaccines
    Table 27: Discontinued Products
    Figure 1: Structure of Human papilloma virus
    Figure 2: Types of HPV genotypes causing Anogenital infections
    Figure 3: Non-genital Warts
    Figure 4: Non-genital Warts
    Figure 5: HPV-AD Products by Indication and Development Status
    Figure 6: HPV-AD Products by Stage and Indication
    Figure 7: Total Drugs for HPV-Associated Diseases
    Figure 8: Late Stage Drugs (Phase III)
    Figure 9: Mid Stage Drugs (Phase II)
    Figure 10: Early Stage Drugs (Phase I and IND)
    Figure 11: Pre-clinical Drugs
    Figure 12: Assessment by Monotherapy Drugs
    Figure 13: Assessment by Route of Administration
    Figure 14: Assessment by Stage and Route of Administration
    Figure 15: Assessment by Molecule Type
    Figure 16: Assessment by Stage and Molecule Type
    Figure 17: Dormant Drugs
    Figure 18: Discontinued Drugs
    Figure 19: Total Vaccines for HPV-AD
    Figure 20: Late Stage Vaccines (Phase III)
    Figure 21: Mid Stage Vaccines (Phase II)
    Figure 22: Early Stage Vaccines (Phase I)
    Figure 23: Pre-clinical Vaccines
    Figure 24: Mid Stage Vaccines (Phase II)
    Figure 25: Early Stage Vaccines (Phase I)
    Figure 26: Pre-clinical Vaccines
    Figure 27: Assessment by Monotherapy Vaccines
    Figure 28: Assessment by Route of Administration
    Figure 29: Assessment by Stage and Route of Administration
    Figure 30: Assessment by Live or Non-live Vaccines
    Figure 31: Assessment by Stage and Live or Non-live Vaccines
    Figure 32: Dormant Vaccines
    Figure 33: Discontinued Products
    Human Papillomavirus Associated Diseases Pipeline Drugs

    Human Papillomavirus Associated Diseases Pipeline Assessment

    Human Papillomavirus Associated Diseases Pipeline Analysis

    Human Papillomavirus Associated Diseases Drugs under Development

    Human Papillomavirus Associated Diseases Discovery drugs

    Human Papillomavirus Associated Diseases Preclinical drugs

    Human Papillomavirus Associated Diseases Phase I drugs

    Human Papillomavirus Associated Diseases Phase II drugs

    Human Papillomavirus Associated Diseases Phase III Pipeline Drugs Assessment

    Human Papillomavirus Associated Diseases Preregistration drugs

    Human Papillomavirus Associated Diseases Molecules in pipeline

    • Single User License
      (20% Off)
      $1,500.00
      $1200
    • Site License
      (30% Off)
      $3,000.00
      $2100
    • Global License
      (40% Off)
      $4,500.00
      $2700

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap